“Liquid biopsy” in which body fluids are screened for biomarkers like circulating tumor cells (CTCs), circulating free DNA, or exosomes are gathering substantial research and support. CTCs are shed into bloodstream from primary tumor, metastases or recurrences, and display tumor specific characteristics, rendering them good candidates for liquid biopsy.
Expression of EpCAM in CTC positive patients predicts chemotherapy resistance and prognosis, could aid clinicians in individualizing therapy, saving the patient from unnecessary side effects and systemic toxicity of platinum-based chemotherapy.
SEE MORE ABOUT TUMOR MARKER RAPID TEST: http://www.alltests.com.cn/
“Liquid biopsy” in which body fluids are screened for biomarkers like circulating tumor cells (CTCs), circulating free DNA, or exosomes are gathering substantial research and support. CTCs are shed into bloodstream from primary tumor, metastases or recurrences, and display tumor specific characteristics, rendering them good candidates for liquid biopsy.
Expression of EpCAM in CTC positive patients predicts chemotherapy resistance and prognosis, could aid clinicians in individualizing therapy, saving the patient from unnecessary side effects and systemic toxicity of platinum-based chemotherapy.
SEE MORE ABOUT TUMOR MARKER RAPID TEST: http://www.alltests.com.cn/
